PAXLOVID (nirmatrelvir/ritonavir)
COVID-19 (SARS-COV-2) ANTIVIRAL-MAIN PROTEASE INHIBITORS · COVID-19
Laboratories Div
Drug class
COVID-19 (SARS-CoV-2) Antiviral-Main Protease Inhibitors
The therapeutic drug class COVID-19 (SARS-CoV-2) Antiviral-Main Protease Inhibitors comprises targeted antiviral agents, such as nirmatrelvir, designed to inhibit the severe acute respiratory syndrome coronavirus 2 main protease, also termed 3CLpro or nsp5. Read more about COVID-19 (SARS-CoV-2) Antiviral-Main Protease Inhibitors
2 drugs in this class 2 manufacturers
Drugs in COVID-19 (SARS-CoV-2) Antiviral-Main Protease Inhibitors
XOCOVA (ensitrelvir fumarate)
COVID-19 (SARS-COV-2) ANTIVIRAL-MAIN PROTEASE INHIBITORS · COVID-19 POST-EXPOSURE PREVENTION
SHIONOGI PHARMA
Filter & compare in the drug finder →
Opens the drug finder with COVID-19 (SARS-CoV-2) Antiviral-Main Protease Inhibitors preselected. Add indication or manufacturer filters there.
The therapeutic drug class COVID-19 (SARS-CoV-2) Antiviral-Main Protease Inhibitors comprises targeted antiviral agents, such as nirmatrelvir, designed to inhibit the severe acute respiratory syndrome coronavirus 2 main protease, also termed 3CLpro or nsp5.
By binding to and blocking this essential viral cysteine protease, these medications prevent the proteolytic processing of viral polyprotein precursors into functional nonstructural proteins, thereby halting viral replication.
Therapeutically, this drug class is utilized for the early treatment of mild-to-moderate COVID-19 in patients who are at high risk for progression to severe illness, hospitalization, or death.
-
nih.gov
The therapeutic drug class COVID-19 (SARS-CoV-2) Antiviral-Main Protease Inhibitors comprises targeted antiviral agents, such as nirmatrelvir, designed to inhibit the severe acute respiratory syndrome coronavirus 2 main protease, also termed 3CLpro or nsp5
-
fda.gov
The therapeutic drug class COVID-19 (SARS-CoV-2) Antiviral-Main Protease Inhibitors comprises targeted antiviral agents, such as nirmatrelvir, designed to inhibit the severe acute respiratory syndrome coronavirus 2 main protease, also termed 3CLpro or nsp5 By binding to and blocking this essential viral cysteine protease, these medications prevent the proteolytic processing of viral polyprotein precursors into functional nonstructural proteins, thereby halting viral replication Therapeutically, ...
-
fda.gov
By binding to and blocking this essential viral cysteine protease, these medications prevent the proteolytic processing of viral polyprotein precursors into functional nonstructural proteins, thereby halting viral replication
-
acs.org
By binding to and blocking this essential viral cysteine protease, these medications prevent the proteolytic processing of viral polyprotein precursors into functional nonstructural proteins, thereby halting viral replication
-
fda.gov
Therapeutically, this drug class is utilized for the early treatment of mild-to-moderate COVID-19 in patients who are at high risk for progression to severe illness, hospitalization, or death
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.